"Clonazepam Orally Disintegrating Tablets, USP (C-IV)" on November 18th, due to "potential product carton strength ...

This past July, we reported on the Centers for Medicare & Medicaid Services (CMS) release of the 2025 proposed Hospital Outpatient Prospective ...

Sanofi's new plan will require institutions to provide pharmacy and medical claims information, such as the drug's order or a ...

The company is worried mislabeling could lead to unintentionally taking higher doses and adverse side effects.

"Children and adults who inadvertently consume a higher dose of clonazepam could be at increased risk for the adverse events ...